Diaminothiazoles modify tau phosphorylation and improve the tauopathy in mouse models

Journal of Biological Chemistry

Volumn 288, Issue 30, 2013, Pages 22042-22056

  Zhang, Xuemei ^a   Hernandez, Israel ^a   Rei, Damien ^b   Mair, Waltraud ^c   K Laha, Joydev ^d   Cornwell, Madison E ^a   Cuny, Gregory D ^d   Tsai, Li Huei ^b   Steen, Judith A J ^c   Kosik, Kenneth S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERPHOSPHORYLATED; IMMUNOREACTIVITIES; KINASE INHIBITION; MOUSE MODELS; TAUOPATHIES;

ENZYME INHIBITION; MAMMALS;

NEURODEGENERATIVE DISEASES;

CYCLIN DEPENDENT KINASE 5; DIAMINOTHIAZOLE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3BETA; LDN 193594; LDN 193665; LDN 212853; LDN 213828; LDN 213842; LDN 213843; PROTEIN P25; TAU PROTEIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; FETUS; IC 50; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; TAUOPATHY; TOXICITY; WESTERN BLOTTING;

ALZHEIMER DISEASE; CDK (CYCLIN-DEPENDENT KINASE); GLYCOGEN SYNTHASE KINASE 3; KINASE INHIBITOR; NEURODEGENERATIVE DISEASES; PROTEIN PHOSPHORYLATION; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE 5; DIAMINES; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; LEARNING; MALE; MEMORY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PRESENILIN-1; PROTEIN KINASE INHIBITORS; TAU PROTEINS; TAUOPATHIES; THIAZOLES; TREATMENT OUTCOME;

EID: 84881260086     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.436402     Document Type: Article

References (42)

1. Wischik, C., and Staff, R. (2009) Challenges in the conduct of diseasemodifying trials in ad: Practical experience from a phase 2 trial of TAUaggregation inhibitor therapy. J. Nutr. Health Aging 13, 367-369
2. Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., Hutton, M. L., and Citron, M. (2011) Passive immunization with anti-Tau antibodies in two transgenic models. J. Biol. Chem. 286, 34457-34467
3. Schmechel, D. E., Gerard, G., Vatakis, N. G., Harper, L., Ross, J. S., Bari, M., Walling, D., Stedman, M., Winston, J. L., Morimoto, B., and Keith, J. R. (2008) P2-377: A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Alzheimers Dement. (suppl), 4, T483
4. Domínguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., and Medina, M. (2012) Evidence for the irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J. Biol. Chem. 287, 893-904
5. Helal, C. J., Kang, Z., Lucas, J. C., Gant, T., Ahlijanian, M. K., Schachter, J. B., Richter, K. E., Cook, J. M., Menniti, F. S., Kelly, K., Mente, S., Pandit, J., and Hosea, N. (2009) Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 19, 5703-5707
6. Helal, C. J., Sanner, M. A., Cooper, C. B., Gant, T., Adam, M., Lucas, J. C., Kang, Z., Kupchinsky, S., Ahlijanian, M. K., Tate, B., Menniti, F. S., Kelly, K., and Peterson, M. (2004) Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. 14, 5521-5525
7. Beaudette, K. N., Lew, J., and Wang, J. H. (1993) Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. J. Biol. Chem. 268, 20825-20830
8. Paudel, H. K., Lew, J., Ali, Z., and Wang, J. H. (1993) Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268, 23512-23518
9. Cruz, J. C., Tseng, H.-C., Goldman, J. A., Shih, H., and Tsai, L.-H. (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483
10. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna, Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L. F., and Duff, K. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565
11. Ishiguro, K. (1992) Tau protein kinase I converts normal Tau protein into A68-like component of paired helical filaments. J. Biol. Chem. 267, 10897-10901
12. Lew, J. (1994) Neuronal cdc2-like kinase is a complex of cyclin-dependent kinase 5 and a novel brain-specific regulatory subunit. Nature 371, 423-426
13. Tsai, L. H., Delalle, I., Caviness, V. S., Jr., Chae, T., and Harlow, E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423
14. Ishiguro, K. (1994) Identification of the 23-kDa subunit of Tau protein kinase II as a putative activator of CDK5 in bovine brain. FEBS Lett. 342, 203-208
15. Sundaram, J. R., Poore, C. P., Sulaimee, N. H., Pareek, T., Asad, A. B., Rajkumar, R., Cheong, W. F., Wenk, M. R., Dawe, G. S., Chuang, K.-H., Pant, H. C., and Kesavapany, S. (2013) Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J. Neurosci. 33, 334-343
16. Piedrahita, D., Hernández, I., López-Tobón, A., Fedorov, D., Obara, B., Manjunath, B. S., Boudreau, R. L., Davidson, B., Laferla, F., Gallego-Gómez, J. C., Kosik, K. S., and Cardona- Gómez, G. P. (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J. Neurosci. 30, 13966-13976
17. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A and synaptic dysfunction. Neuron 39, 409-421
18. Ahn, J. S., Radhakrishnan, M. L., Mapelli, M., Choi, S., Tidor, B., Cuny, G. D., Musacchio, A., Yeh, L. A., and Kosik, K. S. (2005) Defining Cdk5 ligand chemical space with small molecule inhibitors of Tau phosphorylation. Chem. Biol. 12, 811-823
19. Laha, J. K., Zhang, X., Qiao, L., Liu, M., Chatterjee, S., Robinson, S., Kosik, K. S., and Cuny, G. D. (2011) Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors. Bioorg. Med. Chem. Lett. 21, 2098-2101
20. Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., and Tsai, L.-H. (2005) Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48, 825-838
21. Abramoff, M. D., Magelhaes, P. J., and Ram, S. J. (2004) Image processing with ImageJ. Biophotonics Int. 11, 36-42
22. Kvilekval, K., Fedorov, D., Obara, B., Singh, A., and Manjunath, B. S. (0000) Bisque:Aplatform for bioimage analysis and management. Bioinformatics 26, 544-552
23. Greenberg, S. G., and Davies, P. (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. U.S.A. 87, 5827-5831
24. Singh, S., Springer, M., Steen, J., Kirschner, M. W., and Steen, H. (2009) FLEXIQuant: a novel tool for the absolute quantification of proteins, and the simultaneous identification and quantification of potentially modified peptides. J. Proteome Res. 8, 2201-2210
25. Selenica, M. L., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., and Lotharius, J. (2007) Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 152, 959-979
26. Hitchcock, S. A., and Pennington, L. D. (2006) Structure-brain exposure relationships. J. Med. Chem. 49, 7559-7583
27. Olney, J. W., Rhee, V., and Ho, O. L. (1974) Kainic acid: a powerful neurotoxic analogue of glutamate. Brain Res. 77, 507-512
28. Heikkila, R. E., Hess, A., and Duvoisin, R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224, 1451-1453
29. Sloot, W. N., van der Sluijs-Gelling, A. J., and Gramsbergen, J. B. (1994) Selective lesions by manganese and extensive damage by iron after injection into rat striatum or hippocampus. J. Neurochem. 62, 205-216
30. Schmued, L. C., Albertson, C., and Slikker, W., Jr. (1997) Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751, 37-46
31. Oh, K.-J., Perez, S., Lagalwar, S., Vana, L., Binder, L., and Muffson, E. (2010) Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int. J. Alzheimer Dis. 2010, 780102, 24 pp
32. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868
33. Keystone Symposium (2013) New Frontiers in Neurodegenerative Disease Research, Santa Fe, NM, February 4-7, 2013, Keystone Symposia on Molecular and Cellular Biology, Silverthorne, CO
34. Otvos, L., Jr., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., and Lee, V. M. (1994) Monoclonal-antibody PHF-1 recognizes tau protein phosphorylated at serine residue 396 and 404. J. Neurosci. Res. 39, 669-673
35. Lee, V. M., Balin, B. J., Otvos, L., Jr., and Trojanowski, J. Q. (1991) A68-a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678
36. Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., and McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293, 1487-1491
37. Wang, M. S., Boddapati, S., and Sierks, M. R. (2009) Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochem. Biophys. Res. Commun. 386, 526-531
38. Hooper, C., Killick, R., and Lovestone, S. (2008) The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104, 1433-1439
39. Greenberg, S. G., Davies, P., Schein, J. D., and Binder, L. I. (1992) Hydrofluoric acid-treated tau-PHF proteins display the same biochemical- properties as normal tau. J. Biol. Chem. 267, 564-569
40. Hawasli, A. H., Benavides, D. R., Nguyen, C., Kansy, J. W., Hayashi, K., Chambon, P., Greengard, P., Powell, C. M., Cooper, D. C., and Bibb, J. A. (2007) Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. 10, 880-886
41. Li, T., Hawkes, C., Qureshi, H. Y., Kar, S., and Paudel, H. K. (2006) Cyclindependent protein kinase 5 primes microtubule-associated protein Tau site-specifically for glycogen synthase kinase 3β. Biochemistry 45, 3134-3145
42. Lucas, J. J., Hernández, F., Gómez-Ramos, P., Morán, M. A., Hen, R., and Avila, J. (2001) Decreased nuclear-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27-39